Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00769275 · ClinicalTrials.gov registry record

Detection of Ischemia in Asymptomatic Diabetics

A clinical trial of Type 2 Diabetes Mellitus, sponsored by Yale University.

Completed
Registry status
1,123
Enrollment target
1
Study location

NCT00769275: Completed study of Type 2 Diabetes Mellitus, sponsored by Yale University.

NCT00769275 is a study of Type 2 Diabetes Mellitus that has completed, run by Yale University. The registered enrollment target is 1,123 participants, below the 2,951-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00769275, a study of Type 2 Diabetes Mellitus, has completed, sponsored by Yale University.

COMPLETED
Registry status
1,123 participants
Enrollment target
1
Study location

Study Summary

Asymptomatic subjects with Type 2 Diabetes Mellitus were randomized to either screening with Tc-99m sestamibi adenosine SPECT imaging or no screening. All patients will be followed for 5 years for the occurrence of cardiac death or non-fatal myocardial infarction. The aims are: 1. To prospectively assess the prevalence of silent myocardial ischemia in asymptomatic subjects with Type 2 Diabetes Mellitus. 2. To identify on the basis of clinical and/or biochemical variables in a high-risk cohort in which screening for coronary artery disease is appropriate. 3. To assess progression of (silent) myocardial ischemia after 3 years. 4. To assess the occurence of cardiac death or nonfatal myocardial infarction during 5 years follow-up in screened and not screened subjects.

Conditions Studied

Study Locations (1)

Connecticut

  • Yale University School of Medicine - New Haven

Trial Details

FieldValue
Enrollment Target 1,123 participants
Start Date 2000-08
Est. Completion 2008-01
Yale University

1,492 total trials

What the finished NCT00769275 record still lists

NCT00769275 is an observational study that tracks outcomes without assigning an intervention. Its 1,123 participants enrollment target places it among the larger protocols in the corpus, below the 2,951-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (62% lower).

The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 0 interventions.

NCT00769275 reports a single indexed study location in Connecticut.

Frequently Asked Questions

What is clinical trial NCT00769275 about?

NCT00769275 is a clinical study titled "Detection of Ischemia in Asymptomatic Diabetics". Asymptomatic subjects with Type 2 Diabetes Mellitus were randomized to either screening with Tc-99m sestamibi adenosine SPECT imaging or no screening. All patients will be followed for 5 years for the occurrence of cardiac death or non-fatal myocardial infarction. The aims are: 1. To prospectively...

What is the current status of trial NCT00769275?

This trial is currently completed. The enrollment target is 1,123 participants. The study started on 2000-08. Estimated completion is 2008-01.

What conditions does trial NCT00769275 study?

This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.

Who is sponsoring clinical trial NCT00769275?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00769275 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Type 2 Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00769275's enrollment target sits among peer trials

1,123 13th of 130 higher than 118 of 130 other Type 2 Diabetes Mellitus trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Type 2 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05438329 · 1,123 participants · Phase 1

    First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors

  • NCT06952504 · 1,123 participants · Phase 3

    A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

  • NCT05691478 · 1,122 participants · Phase 2

    A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

  • NCT04421768 · 1,125 participants · NA

    Effects of Systematic Cervical Exam Training on Labor and Delivery Care

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00769275, the US trial registry maintained by the National Library of Medicine. NCT00769275 (large enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.